TG Therapeutics二季度收入和BRIUMVI指引上调但EPS大幅不及预期

Earnings Call Insights: TG Therapeutics (TGTX) Q2 2026
Management View
- "The second quarter of 2026 was another quarter of strong execution" and "marked an important evolution for TG Therapeutics," as "BRIUMVI is enabling us to build something much bigger" spanning "new formulations and new indications" and "thoughtful business development" (Chairman, CEO & President Michael Weiss).
- "We delivered another excellent quarter, once again exceeding our guidance" with "new patient starts" growing and "physician adoption" expanding; management reiterated the aim "to become the #1 prescribed anti-CD20 therapy in relapsing MS based on dynamic market share" (CEO Weiss).
- "We announced positive top line Phase III results from our ENHANCE study" to enable "a single 600-milligram infusion" initiation, which management said could reduce switching barriers; "this new initiation schedule could be available as early as the middle of next year" (CEO Weiss).
- "We reported positive Phase I bioavailability data" for subcutaneous ublituximab and said Phase III is "fully enrolled" with "top line Phase III results around year-end or early next year"; management framed subcu as expanding coverage beyond the "approximately 60% to 65%" physician-administered segment and stated, "the subcu opportunity has the potential to more than double BRIUMVI's current addressable market" (CEO Weiss).
- "We generated approximately $228 million in U.S. BRIUMVI net product revenue with global revenue exceeding $240 million" and "we're raising our full year U.S. BRIUMVI net revenue guidance to $890 million to $905 million" while "now expect[ing] approximately $950 million in total global revenue for 2026" (Chief Commercialization Officer Adam Waldman).
- "Total revenue for the quarter was $240 million" and "net income of $7.8 million or $0.05 per diluted share"; Sean Power highlighted OpEx of "approximately $150 million" including "roughly $55 million" of subcutaneous and secondary-source manufacturing charges (CFO Sean Power).
Outlook
- "We're raising our full year U.S. BRIUMVI net revenue guidance to $890 million to $905 million" and "now expect approximately $950 million in total global revenue for 2026" (CCO Waldman).
- "We expect the fourth quarter to drive second half growth" and plan to "exit 2026 with quarterly U.S. net revenue exceeding $250 million" and "setting the stage for our first $1 billion-plus U.S. BRIUMVI revenue year in 2027" (CCO Waldman).
- Management described ENHANCE as supporting a potential launch timeline where the new initiation schedule "could be available as early as the middle of next year" (CEO Weiss).
- Versus Q1, management moved from "around year-end or early next year" Phase I subcu bioavailability data timing to reporting "positive Phase I bioavailability data" in Q2, while keeping Phase III timing as "around year-end or early next year" (CEO Weiss).
Financial Results
- Q2 total revenue was "$240 million" vs. $229,787,340 revenue estimate; Q2 diluted EPS was "$0.05" vs. $0.44 EPS estimate (CFO Power; analystsEstimates).
- "Gross margin of our U.S. business" was "approximately 87%" and total gross margin was "83%" (CFO Power).
- CFO Power said underlying OpEx was "about $95 million" after excluding the "roughly $55 million" manufacturing charges; he added the company expects "approximately $100 million" of these manufacturing activities in 2026.
- The company ended Q2 with "approximately $612 million in cash, cash equivalents and investment securities" (CFO Power).
Q&A
- Gregory Wiessner, TD Cowen: asked how peak sales assumptions differ for quarterly vs every-2-month subcu dosing; Chief Commercialization Officer Waldman: "we haven't given specific guidance" but "we do think a less frequent dose is going to be better than a more frequent dose."
- Prakhar Agrawal, Cantor Fitzgerald: asked about Part D pricing/contracting and uptake for subcu, OpEx drivers, and ex-U.S. partner revenue; CCO Waldman: "we're not going to talk about pricing yet" but "we do think we can price it competitively" and "we think the uptake will be strong"; CEO Weiss added field feedback that "the enthusiasm and excitement for the subcu product is pretty incredible"; CFO Power cited DTC/SG&A plus "the $100 million in subcutaneous manufacturing" and said global guidance also reflects "license and milestone related revenue" (Waldman/Weiss/Power).
- Michael DiFiore, Evercore ISI: asked if share gains are accelerating and sources (switches vs naïve) and schizophrenia study decision criteria; CCO Waldman: "we're seeing it from both switches from OCREVUS and treatment-naive patients"; CEO Weiss described a "Fleming 2-stage design" and said moving forward depends on clearing "the hurdle rate of responders" (Waldman/Weiss).
- Emily Bodnar, H.C. Wainwright: asked IV market growth post-subcu and new azer-cel indications; CEO Weiss: "we expanded the study into relapsing MS, MG, CIDP and NMO"; management emphasized "patient empowerment" and "choice" across IV and self-administered routes (Weiss/Waldman).
- William Wood, B. Riley: asked about implied Q3 flatness and 2027 growth; CCO Waldman cited "seasonal dynamics" and said focus is "the full year guidance"; CEO Weiss said 2027 guidance is not provided yet and positioned ENHANCE as a 2027 catalyst and subcu as "an order of magnitude change" with a 2028 timeline (Waldman/Weiss).
- Prakhar Agrawal, Cantor Fitzgerald: asked about gross-to-net and BD appetite; CCO Waldman: "Gross to net is basically unchanged" and "mid-60s"; CEO Weiss: "We're not looking for any major consolidation plays" and is focused on assets that "create value without stressing our bank accounts" (Waldman/Weiss).
Sentiment Analysis
- Analysts’ tone was slightly positive with repeated forward-looking commercial and pipeline framing ("Congrats on the quarter"; multiple questions on subcu differentiation, pricing, and competitive dynamics), alongside slightly skeptical probing on quarter phasing, gross-to-net, and BD (Wiessner/Agrawal/Wood/DiFiore).
- Management’s tone was positive and expansion-oriented in prepared remarks ("important evolution"; "starting line for continued innovation") and remained confident in Q&A, including emphasis on demand signals ("enthusiasm and excitement") while declining specifics on pricing (CEO Weiss; CCO Waldman).
- Versus Q1, management maintained confidence on becoming a larger platform, but shifted from discussing upcoming ENHANCE and Phase I subcu bioavailability data to stating both as positive/complete (ENHANCE top-line positive; Phase I bioavailability positive) (CEO Weiss).
Quarter-over-quarter Comparison
- Q2 raised full-year guidance to "$890 million to $905 million" U.S. net revenue and "approximately $950 million" global revenue vs. Q1 guidance of "$885 million to $900 million" U.S. and "approximately $925 million" global (CCO Waldman; CFO Power in Q1).
- Q2 emphasized ENHANCE as already "positive top line Phase III results" vs. Q1 describing ENHANCE data expected "in the coming weeks" (CEO Weiss).
- Q2 expanded azer-cel indication list explicitly to "relapsing MS, MG, CIDP and NMO" vs. Q1 discussing azer-cel primarily in progressive MS and site interest (CEO Weiss).
- Analyst focus stayed centered on subcu differentiation and cadence; Q2 added more direct competition framing around Roche comments and more detailed commercialization mechanics (Part D pricing, DTC scaling) (DiFiore/Agrawal/Q1-Q2 exchanges).
Risks and Concerns
- Management cited execution dependencies for subcu timing: "We've got a few other studies we'll need to do... including the bridge to the auto-injector" and noted the constraint of "about a 12-month review process" (CEO Weiss, from Q1; Q2 reiterated timing expectations).
- Management highlighted quarter-to-quarter variability risk in demand patterns: Q3 has "some seasonal dynamics" and "gross to net can vary from quarter-to-quarter" while reiterating annual expectations (CCO Waldman).
- On new indications, management framed schizophrenia as exploratory with decision gates based on response hurdles and biomarkers, stating, "we'll look at the data" if below target and may evaluate subgroups (CEO Weiss).
Final Takeaway
Management described Q2 as a step-change quarter driven by higher BRIUMVI revenue, a higher 2026 outlook, and multiple pipeline catalysts, including positive ENHANCE Phase III results to simplify IV initiation, a fully enrolled subcutaneous Phase III program with results expected around year-end or early next year, and earlier-stage expansion into myasthenia gravis, schizophrenia, and broader azer-cel indications, while keeping capital allocation focused on investing behind BRIUMVI, pipeline advancement, selective business development, and share repurchases.
Read the full Earnings Call Transcript